WallStSmart

Novo Nordisk A/S (NVO)vsSherwin-Williams Co (SHW)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novo Nordisk A/S generates 1211% more annual revenue ($309.06B vs $23.57B). NVO leads profitability with a 33.1% profit margin vs 10.9%. SHW appears more attractively valued with a PEG of 2.63. NVO earns a higher WallStSmart Score of 55/100 (C).

NVO

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 10.0Value: 4.7Quality: 4.8
Piotroski: 3/9Altman Z: 2.08

SHW

Buy

54

out of 100

Grade: C-

Growth: 4.7Profit: 7.5Value: 4.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVOSignificantly Overvalued (-59.4%)

Margin of Safety

-59.4%

Fair Value

$24.21

Current Price

$36.33

$12.12 premium

UndervaluedFair: $24.21Overvalued
SHWSignificantly Overvalued (-237.9%)

Margin of Safety

-237.9%

Fair Value

$92.84

Current Price

$321.95

$229.11 premium

UndervaluedFair: $92.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVO5 strengths · Avg: 9.8/10
P/E RatioValuation
10.4x10/10

Attractively priced relative to earnings

Return on EquityProfitability
60.7%10/10

Every $100 of equity generates 61 in profit

Profit MarginProfitability
33.1%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
44.5%10/10

Strong operational efficiency at 44.5%

Market CapQuality
$165.02B9/10

Large-cap with strong market position

SHW2 strengths · Avg: 9.5/10
Return on EquityProfitability
59.4%10/10

Every $100 of equity generates 59 in profit

Market CapQuality
$77.79B9/10

Large-cap with strong market position

Areas to Watch

NVO4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.882/10

Expensive relative to growth rate

Revenue GrowthGrowth
-7.6%2/10

Revenue declined 7.6%

EPS GrowthGrowth
-4.7%2/10

Earnings declined 4.7%

SHW4 concerns · Avg: 3.5/10
P/E RatioValuation
30.6x4/10

Premium valuation, high expectations priced in

Price/BookValuation
17.2x4/10

Trading at 17.2x book value

EPS GrowthGrowth
1.4%4/10

1.4% earnings growth

PEG RatioValuation
2.632/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : NVO

The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.1% and operating margin at 44.5%.

Bull Case : SHW

The strongest argument for SHW centers on Return on Equity, Market Cap.

Bear Case : NVO

The primary concerns for NVO are Piotroski F-Score, PEG Ratio, Revenue Growth.

Bear Case : SHW

The primary concerns for SHW are P/E Ratio, Price/Book, EPS Growth.

Key Dynamics to Monitor

NVO profiles as a declining stock while SHW is a value play — different risk/reward profiles.

SHW carries more volatility with a beta of 1.24 — expect wider price swings.

SHW is growing revenue faster at 5.6% — sustainability is the question.

SHW generates stronger free cash flow (862M), providing more financial flexibility.

Bottom Line

NVO scores higher overall (55/100 vs 54/100), backed by strong 33.1% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novo Nordisk A/S

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

Sherwin-Williams Co

BASIC MATERIALS · SPECIALTY CHEMICALS · USA

Sherwin Williams Company is a Cleveland, Ohio based company in the paint and coating manufacturing industry. The company primarily engages in the manufacture, distribution, and sale of paints, coatings, floorcoverings, and related products to professional, industrial, commercial, and retail customers primarily in North and South America and Europe.

Want to dig deeper into these stocks?